Scottish Biomedical and ARYx join forces
Scottish Biomedical of Glasgow, UK, and ARYx Therapeutics of Santa Clara, CA, have entered a research and development collaboration where Scottish Biomedical will generate a stable cell line on behalf of ARYx, for specific receptor cloning.
Scottish Biomedical of Glasgow, UK, and ARYx Therapeutics of Santa Clara, CA, have entered a research and development collaboration where Scottish Biomedical will generate a stable cell line on behalf of ARYx, for specific receptor cloning.
Simon Bury, business development director at Scottish Biomedical commented: 'We are delighted to have the opportunity to work with ARYx. The agreement reflects the progress of Scottish Biomedical's business growth in the US and we are looking forward to a rewarding relationship.'